ADMA Biologics ADMA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Business Acquisitions Pro Forma Revenue by Business | ||||||
| ADMA Bio Manufacturing | $113.74M0.0% | —— | —— | —— | $113.72M— | |
| Plasma Collection Centers | $716K-31.8% | —— | —— | —— | $1.05M— | |
| Revenue by Business | ||||||
| ADMA Bio Manufacturing | $113.74M0.0% | $123.29M+10.1% | $134.19M+14.0% | $121.95M+14.8% | $113.72M+41.9% | |
| Plasma Collection Centers | $716K-31.8% | $15.98M+179% | $0-100% | $0-100% | $1.05M-39.2% | |
| Nonoperating Income Expense by Business | ||||||
| ADMA Bio Manufacturing | -$187K-192% | -$7K+90.7% | -$21K+62.5% | -$108K-731% | -$64K-113% | |
| Plasma Collection Centers | $68K— | -$10K-900% | $0— | $0+100% | $0+100% | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest by Business | ||||||
| ADMA Bio Manufacturing | 6,229,800,000%+1,709,300,000pp | 9,320,300,000%+4,292,400,000pp | 5,146,000,000%+228,100,000pp | 4,521,100,000%-149,100,000pp | 4,520,500,000%+1,653,900,000pp | |
| Plasma Collection Centers | 690,900,000%+779,300,000pp | -186,300,000%-7,900,000pp | -146,400,000%-50,300,000pp | -115,200,000%+8,800,000pp | -88,400,000%+17,200,000pp | |
| Cost Of Revenue by Business | ||||||
| ADMA Bio Manufacturing | $32.95M-37.9% | $33.64M-29.9% | $58.41M+0.4% | $54.76M+13.0% | $53.06M+29.4% | |
| Plasma Collection Centers | $793K+22.4% | $16.71M+168% | $192K-90.5% | $0-100% | $648K-63.5% | |
| Gain On Sale Of Investments by Business | ||||||
| ADMA Bio Manufacturing | $0— | —— | —— | —— | —— | |
| Plasma Collection Centers | $7.98M— | —— | —— | —— | —— | |
| Total Assets by Business | ||||||
| ADMA Bio Manufacturing | $429.29M+30.1% | $441.51M+52.6% | $403.92M+51.6% | $368.23M+42.7% | $330.09M+18.6% | |
| Plasma Collection Centers | $25.26M-8.6% | $28.49M-6.5% | $27.03M-18.6% | $29.16M-13.2% | $27.64M-18.7% | |
| Selling And Marketing Expense by Business | ||||||
| ADMA Bio Manufacturing | $7.2M+19.1% | $6.68M+25.8% | $8.15M+38.1% | $5.87M+30.3% | $6.04M+36.4% | |
| Plasma Collection Centers | $0— | $0— | $0— | $0— | $0— | |
| Segment Expenditure Addition To Long Lived Assets by Business | ||||||
| ADMA Bio Manufacturing | $2.52M-46.5% | $1.02M-61.3% | $14.65M+1,273% | $2.03M+68.1% | $4.7M+102% | |
| Plasma Collection Centers | $27K+28.6% | $244K+107% | $292K+3,144% | -$7K-112% | $21K+23.5% | |
| General And Administrative Expense by Business | ||||||
| ADMA Bio Manufacturing | $8.46M-0.4% | —— | $14.59M+266% | $14.94M+158% | $8.5M+58.8% | |
| Plasma Collection Centers | $0— | $0— | $0— | $0— | $0— | |
| Research And Development Expense by Business | ||||||
| ADMA Bio Manufacturing | $2.6M+214% | $1.38M+252% | $1.53M+271% | $1.03M+84.1% | $826K+83.1% | |
| Plasma Collection Centers | $0— | $0— | $0— | $0— | $0— | |
| Stock-Based Comp by Business | ||||||
| ADMA Bio Manufacturing | $0— | —— | —— | —— | $0— | |
| Plasma Collection Centers | $1.06M-17.4% | —— | —— | —— | $1.29M— | |
| Depreciation And Amortization by Business | ||||||
| ADMA Bio Manufacturing | $1.27M+9.7% | —— | —— | —— | $1.16M+502% | |
| Plasma Collection Centers | $565K-30.1% | —— | —— | —— | $808K— | |
| Revenue by Product | ||||||
| ASCENIV | $97.49M+27.7% | —— | —— | —— | $76.33M+27.4% | |
| BIVIGAM | $15.42M-54.0% | —— | —— | —— | $33.51M-5.8% | |
| Intermediates And Other | $833K-78.5% | —— | —— | —— | $3.87M-54.4% | |
| Revenue by Geography | ||||||
| Non Us | $1.07M-73.8% | $1.79M-37.6% | $246K-95.2% | $0-100% | $4.07M+4.8% | |
| US | $113.43M+2.4% | $137.38M+19.8% | $133.98M+16.8% | $121.98M+18.7% | $110.73M+42.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ADMA Biologics break its business down?
- ADMA Biologics (ADMA) reports business acquisitions pro forma revenue by business across 2 parts — ADMA Bio Manufacturing and Plasma Collection Centers. Each is extracted from the segment footnotes and tracked over time.
- Where does ADMA Biologics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ADMA Biologics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
